European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk.

@article{Landmesser2017EuropeanSO,
  title={European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk.},
  author={Ulf Landmesser and Martin John Chapman and Michel Farnier and Baris Gencer and Stephan Gielen and G. K. Hovingh and Thomas Felix L{\"u}scher and David Sinning and Lale Tokg{\"o}zoğlu and Olov Wiklund and Jose Luis Zamorano and F. J. V. Pinto and Alberico L. Catapano},
  journal={European heart journal},
  year={2017},
  volume={38 29},
  pages={2245-2255}
}
Department of Cardiology, Charité—Universit€atsmedizin Berlin (CBF), Hindenburgdamm 30, 12203 Berlin, Berlin Institute of Health (BIH), and Deutsches Zentrum für HerzKreislaufforschung (DZHK), Germany; National Institute for Health and Medical Research (INSERM), University of Pierre and Marie Curie, Pitié-Salpêtrière Hospital, 47 Hôpital boulevard, Paris, 75013 France; Lipid Clinic, Point Medical, Dijon, France; Cardiology Division, Department of Specialties in Medicine, Geneva University… CONTINUE READING